authors
-
Barbara Pieńkowska-Grela 1, Roman Sosnowski 2, Tomasz Demkow 2
- 1 Samodzielna Pracownia Cytogenetyki Centrum Onkologii w Warszawie
Kierownik pracowni: dr n. med. B. Pieńkowska-Grela
2 Klinika Nowotworów Układu Moczowego Centrum Onkologii w Warszawie
Kierownik kliniki: dr n. med. T. Demkow
keywords
-
testis testicular germ cell tumor chromosomal aberations isochromosome i(12p) ? results of treatment
summary
- Malignant transformation may by caused by gene deregulation resulting from
- specific chromosomal rearrangements. Adult testicular germ cell tumors (TGCT)
- for clinical and pathological reasons divided in seminoma (SE) and non-
- seminoma (NS), arise by transformation of germ cell. In most patients these
- tumors are cured using cisplatin-based Combination chemotherapy. Important
- steps in the TGCT oncogenesis seem to be polyploidization and formation of
- the i(12p) marker chromosome. Cytogenetic studies have shown that
- multiplication of 12p manifested in the i(12p) marker (in 80% of cases) or in
- aberrant markers containing chromosome 12p material constitutes a uniąue
- change in GCT which can be used as diagnostic marker. The consistent
- amplification of critical 12p region in all histological subtypes of TGCT indicates
- that this genetic abnormality could play an critical role in the ethiology, progres-
- sion or prognosis of these tumors.
references
- [1] Atkin, N: B.: High chromosome number of seminomała and malignant teratoma
- of the testis: a review of data 103 tumours. Br. J. Cancer 1973, 28, 275-278.
- [2] Atkin, N. B., Baker, M. C: i(12p): Specific chromosomal marker in seminoma and
- malignant teratoma of the testis?. Cancer Genet. Cytogenet. 1983,10,199-204.
- [3] Bosi, G. ]., Geller, N. L., Bajorin, D., Leitner, S. R, Yagoda, A., Golbey,
- R. B., Scher, H., Yogelzang, N. ]., Auman ]., Carey, R., et al: A random-
- ized trial ofetopside + cisplatin versus vinblastine + bleomycin + cispaltin + cyclo-
- phosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J.
- Clin. Oncol. 1988, 6,1231-1238.
- [4] Bosi, G. }., et al.: Clinical relevance of the i(12p) marker chromosome in germ cell
- tumors.}. Natl. Cancer Inst. 1994, 86, 349-355.
- [5] Bosi, G. J., et al.: Isochromosome of the short arm of chromosome 12: Clinically
- useful markers for male germ cell tumors. J. Nat. Cancer Inst. 1989, 81, 1874-
- 1878.
- [6] Bosi, G. J., et al.: The use of tumor markers in germ cell malignancies. Hematol.
- Oncol. Clin. North Am. 1994 , 8, 573-587.
- [7] Brecher, R., et al.: Use of fluorescence in situ hybridization and comparative gen-
- omic hybridization in the cytogenetic analysis of testicular germ cell tumors and
- uveal melanoma. Cancer Genet. Cytogenet. 1997, 93, 22-28.
- [8] Castedo, S. M., de Jong, Oosterhuis, ]. W., Seruca, R., et al.: Chromosom-
- al changes in human primary testicular nonseminomatous germ cell tumors. Can-
- cer Res. 1989, 49, 5696-5701.
- [9] Einhorn, L. H., Williams, S. D., Loehrer, P. ]., Birch, R., Drasga, R.,
- Omura, G., Greco, F. A.: Evaluation of optimal duration of chemotherapy in
- fanorable-prognosis disseminated germ. cell tumors: a Southeastern Cancer Study
- Group protocol. J. Clin. Oncol. 1989, 7, 387-391.
- [10] El-Naggar, A. K., Ro, J. Y., McLemore, D., et al.: DNA ploidy in testicular
- germ cell neoplasms. Histogenic and clinical implications. Am. J. Surg. Pathol.
- 1992,16, 611-618.
- [11] Ewing, J.: Teratoma testis and its deriimtes. Surg. Gynecol. Obstet. 1991, 12,
- 230-261.
- [12] Friedman, N. B.: The comparative morphogenesis of extragenital and gonadal
- tetretoid tumors. Cancer 1951, 4, 265-276.
- [13] Haim, S., Mitelman, F., et al.: Cancer Cytogenetics (Second edition). Willey-
- Liss, 1995, 69-140,166-179.
- [14] Uson, D. H., Bosi, G. J., Dimitrovsky, E., Chaganti, R. S.: Genetic analy-
- sis of germ cell tumors: current progress and future prospects. Hematol. Oncol.
- Clin. North. Am. 1991, 5,1271-1283.
- [15] Mostert, M. C, Verkerk, A. J.: Identification of the critical region of lip over-
- representation in TGCT of adolescent and adults. Oncogene. 1998,16,2617-2627.
- [16] Motzer, R. )., Cooper, K., Geller, N. L., Pfister, D. G., Lin, S-Y., Bajo-
- rin, D.~, Scher,- H. I., Herr, H., Fair, W., Morse, M., Sogani, P., Whitmo-
- re, W., Bosi, G. J.: Carboplatin + etoposide + bleomycin for patient with poor risk
- germ cell tumors. Cancer 1990, 65, 2465-2470.
- [17] Motzer, R. }., Geller, N., Bajorin, D., Scher, H., Tan, C, Hen, H., Soga-
- ni, P., Fair, W., Morse, M., Russo, P., Bosi, G.: Sahage chemotherapy for
- germ cell tumor patients: prior complete response as an important prognostic vari-
- able (Abstarct). Proc. Am. Soc. Clin. Oncol. 1990, 9,141.
- [18] Motzer, R. J., Rodriguez, E., Reuter, V. E? Bosi, G. J., Mazumdar, M.,
- Chaganti, R. K.: Molecular and cytogenetic studies in the diagnosis of patients
- with poorly differentiated carcinomas of unknown primary site. J. Clin. Oncol. 1995,
- 13, 274-282.
- [19] Nowel, P. C, Hungerford, D. A.: A minutę chromosome in human granulo-
- citic leukemia. Science 1960,132,1497.
- [20] Peltomaki, P., et al: Chromosome 12 in human testicular cancer: Dosage chan-
- ges and their parental origin. Cancer Genet. Cytogenet. 1992, 64, 21-26.
- [21] Pieńkowska, B., Grygalewicz, B., Witkowska, A.: Analiza występowania
- izochromosomu i(12p) w ludzkich guzach jąder przy zastosowaniu techniki fluore-
- scencyjnej hybrydyzacji in situ. Gin. Pol. 1997, 86, 274-251.
- [22] Pieńkowska, B., et al.: Analiza kariotypowa nowotworów jąder u człowieka.
- Nowotwory 1997, 47,108-119.
- [23] Rodriguez, E., Mathew, S., Router, V., et al.: Cytogenetic analysis of 124
- prospectwely ascertained male germ cell tumors. Cancer Res. 1992,52,2285-2291.
- [24] Summersgill, B., et al.: Molecular cytogenetic analysis of adult testicular germ
- cell tumours and identification ofregions of consensus copy number change. Br. J.
- Cancer 1998, 77, 305-313.
- [25] Tijo, J. Fl., Levan, A.: The chromosome number of man. Hereditas 1956,42,1-6.
- [26] Toner, G. C, Lin, S. Y., Geller, N. L., Ochoa, M., Bosi, G. J.: Survival and
- Prognostic featurs of extragonadal and poor risk nonseminomatous germ cell tu-
- mours. Proc. Am. Assoc. Cancer Res. 1989, 30, 259.
- [27] Vincent, T., et al.: Cancer: Principles and Practice of Oncology, Fourth Edition.
- 1993,1126-1132.
- [28] Zatoński, W., Tyczyński, J. (red.): Nowotwory złośliwe w Polsce w 1995. Za-
- kład Epidemiologii i Prewencji Nowotworów, Krajowy Rejestr Nowotwo-
- rów, 1998, Pracownia Poligraficzna Centrum Onkologii - Instytut.
|